Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...

Biogen: Biogen, a leading biotechnology company ... including smartphones, tablets, and smart home devices. Their 5G chipsets offer high-speed connectivity, power efficiency, and advanced features ...

Semaglutide is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes and as Wegovy ... Kisunla is ...

Semaglutide is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes ... the market to treat ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of ...

Biogen is making a few changes to its C-suite. The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a move announced one day after ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...